Oncozenge AB (ONCOZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncozenge AB (ONCOZ) has a cash flow conversion efficiency ratio of -0.377x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.51 Million ≈ $-377.73K USD) by net assets (Skr9.30 Million ≈ $1.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncozenge AB - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Oncozenge AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Oncozenge AB for a breakdown of total debt and financial obligations.
Oncozenge AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncozenge AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dovre Group Plc
HE:DOV1V
|
-0.894x |
|
Newcity (Bangkok) Public Company Limited
BK:NC
|
-0.037x |
|
Fountain
BR:FOU
|
0.287x |
|
Patkol Public Company Limited
BK:PK
|
0.024x |
|
Resources & Energy Group Ltd
AU:REZ
|
-0.019x |
|
Kwang Hee Self-Administered Real Estate
KO:140910
|
-0.011x |
|
Pacific Ridge Exploration Ltd
V:PEX
|
-0.506x |
|
MESB Bhd
KLSE:7234
|
0.001x |
Annual Cash Flow Conversion Efficiency for Oncozenge AB (2020–2024)
The table below shows the annual cash flow conversion efficiency of Oncozenge AB from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see ONCOZ market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr9.95 Million ≈ $1.07 Million |
Skr-8.76 Million ≈ $-943.15K |
-0.881x | +3.89% |
| 2023-12-31 | Skr18.64 Million ≈ $2.01 Million |
Skr-17.08 Million ≈ $-1.84 Million |
-0.916x | -41.02% |
| 2022-12-31 | Skr33.97 Million ≈ $3.66 Million |
Skr-22.08 Million ≈ $-2.38 Million |
-0.650x | -995.02% |
| 2021-12-31 | Skr80.32 Million ≈ $8.64 Million |
Skr-4.77 Million ≈ $-513.01K |
-0.059x | -173676.54% |
| 2020-12-31 | Skr29.28 Million ≈ $3.15 Million |
Skr-1.00K ≈ $-107.62 |
0.000x | -- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.